BRAF mutation is associated with improved local control of melanoma brain metastases treated with Gamma Knife radiosurgery

Frontiers in Oncology

Volumn 6, Issue MAY, 2016, Pages

  Gallaher, Ian S ^a   Watanabe, Yoichi ^a   DeFor, Todd E ^a   Dusenbery, Kathryn E ^a   Lee, Chung K ^a   Hunt, Matthew A ^a   Lin, Hong Yiou ^b   Yuan, Jianling ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

BRAF; Brain metastases; Gamma knife; Melanoma; Stereotactic radiosurgery

Indexed keywords

B RAF KINASE; DABRAFENIB; GADOLINIUM; VEMURAFENIB;

ADULT; ARTICLE; BRAIN METASTASIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RETROSPECTIVE STUDY; TUMOR VOLUME; UNIVARIATE ANALYSIS; YOUNG ADULT;

EID: 84973535583     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00107     Document Type: Article

References (32)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin (2015) 65:5-29. doi: 10.3322/caac.21254
2. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer (2002) 94:2698-705. doi:10.1002/cncr.10541
3. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg (1998) 88:11-20. doi:10.3171/jns.1998.88.1.0011
4. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2011) 117:1687-96. doi:10.1002/cncr.25634
5. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol (2012) 30:419-25. doi:10.1200/JCO.2011.38.0527
6. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 10:1037-44. doi:10.1016/S1470-2045(09)70263-3
7. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG, et al. A European organisation for research and treatment of cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol (2013) 31:65-72. doi:10.1200/JCO.2011.41.0639
8. NCCN. Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. V.2 [Internet]. (2014). Available from: www.nccn.org
9. Lin H, Watanabe Y, Cho LC, Yuan J, Hunt MA, Sperduto PW, et al. Gamma knife stereotactic radiosurgery for renal cell carcinoma and melanoma brain metastases-comparison of dose response. J Radiosurg SBRT (2013) 2:193-207
10. Lo SS, Clarke JW, Grecula JC, McGregor JM, Mayr NA, Cavaliere R, et al. Stereotactic radiosurgery alone for patients with 1-4 radioresistant brain metastases. Med Oncol (2011) 28:439-44. doi:10.1007/s12032-010-9670-5
11. Powell JW, Chung CT, Shah HR, Canute GW, Hodge CJ, Bassano DA, et al. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg (2008) 109(Suppl):122-8. doi:10.3171/JNS/2008/109/12/S19
12. Liew DN, Kano H, Kondziolka D, Mathieu D, Niranjan A, Flickinger JC, et al. Outcome predictors of gamma knife surgery for melanoma brain metastases: clinical article. J Neurosurg (2011) 114:769-79. doi:10.3171/2010.5.JNS1014
13. Molenaar R, Wiggenraad R, Verbeek-de Kanter A, Walchenbach R, Vecht C. Relationship between volume, dose and local control in stereotactic radiosurgery of brain metastasis. Br J Neurosurg (2009) 23:170-8. doi:10.1080/02688690902755613
14. Johung KL, Yao X, Li F, Yu JB, Gettinger SN, Goldberg S, et al. A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer. Clin Cancer Res (2013) 19:5523-32. doi:10.1158/1078-0432.CCR-13-0836
15. Lee HL, Chung TS, Ting LL, Tsai JT, Chen SW, Chiou JF, et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol (2012) 7:181. doi:10.1186/1748-717X-7-181
16. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 3:11-22. doi:10.1038/nrc969
17. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 29:1239-46. doi:10.1200/JCO.2010.32.4327
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417:949-54. doi:10.1038/nature00766
19. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys (2000) 47:291-8. doi:10.1016/S0360-3016(99)00507-6
20. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 45:228-47. doi:10.1016/j.ejca.2008.10.026
21. McMahon JM, Pouget ER, Tortu S. A guide for multilevel modeling of dyadic data with binary outcomes using SAS PROC NLMIXED. Comput Stat Data Anal (2006) 50:3663-80. doi:10.1016/j.csda.2005.08.008
22. Ripatti S, Palmgren J. Estimation of multivariate frailty models using penalized partial likelihood. Biometrics (2000) 56:1016-22. doi:10.1111/j.0006-341X.2000.01016.x
23. Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg (2015) 123:395-401. doi:10.3171/2014.9.JNS141425
24. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol (2013) 113:411-6. doi:10.1007/s11060-013-1127-1
25. Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol (2015) 122:121-6. doi:10.1007/s11060-014-1685-x
26. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 363:809-19. doi:10.1056/NEJMoa1002011
27. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 379:1893-901. doi:10.1016/S0140-6736(12)60398-5
28. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol (2011) 98:394-9. doi:10.1016/j.radonc.2010.12.017
29. Dasgupta T, Yang X, Hashizume R, Olow A, Kolkowitz I, Weiss W, et al. Survival advantage with radiation combined with a selective BRAFV600E inhibitor in an orthotopic, intracranial model of BRAFV600E-mutated high-grade gliomas. Int J Radiat Oncol Biol Phys (2012) 84:S125. doi:10.1016/j.ijrobp.2012.07.125
30. Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, et al. On demand gamma-knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol (2014) 25:2086-91. doi:10.1093/annonc/mdu266
31. Kotecha R, Venur VA, Murphy ES, Yu JS, Chao ST, Suh JH, et al. Impact of BRAF mutation on outcome following stereotactic radiosurgery in melanoma brain metastases. Int J Radiat Oncol Biol Phys (2015) 93:S58. doi:10.1016/j.ijrobp.2015.07.139
32. Holdaway I, Bowditch J. Variation in receptor status between primary and metastatic breast cancer. Cancer (1983) 52:479-85. doi:10.1002/1097-0142(19830801)52:3<479::AID-CNCR2820520317>3.0.CO;2-O